SCHEMBL2071464

SCHEMBL2071464

Cc1cc(C)c(-c2cn(C)c3nc(NCc4ccc5ccccc5c4)n(C)c(=O)c23)c(C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 7/20 0.53
TSHR P16473 1/20 0.40
MAPK13 O15264 2/20 0.38
MAPK9 P45984 2/20 0.38
MAPK14 Q16539 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MAP4K4 O95819 1/20 0.38
EGFR P00533 1/20 0.38
ERBB2 P04626 1/20 0.38
LYN P07948 1/20 0.38
PRKACA P17612 1/20 0.38
PRKCI P41743 1/20 0.38
MAPK8 P45983 1/20 0.38
CSNK1D P48730 1/20 0.38
MAPK12 P53778 1/20 0.38
MAPK10 P53779 1/20 0.38
MAP3K10 Q02779 1/20 0.38
PRKCZ Q05513 1/20 0.38
PRKCD Q05655 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2071039 0.86 CRHR1 (0.54) CRHR1TSHRNPC1RAB9AMAPT
SCHEMBL2072033 0.85 CRHR1 (0.52) CRHR1TSHRMAPTALDH1A1PKM
SCHEMBL2072594 0.82 CRHR1 (0.46) CRHR1TSHRNPC1RAB9AMAPT
SCHEMBL2069529 0.82 CRHR1 (0.68) CRHR1ALDH1A1HIF1ASMN1; SMN2NR3C1
SCHEMBL2072641 0.81 CRHR1 (0.66) CRHR1TSHRRAB9AMAPTALDH1A1
SCHEMBL2071199 0.80 CRHR1 (0.52) CRHR1RAB9AALDH1A1HIF1AGAA
SCHEMBL2070177 0.77 CRHR1 (0.49) CRHR1GAA
SCHEMBL2072342 0.76 CRHR1 (0.57) CRHR1HIF1AGAAKMT2ASMN1; SMN2
SCHEMBL2073108 0.74 CRHR1 (0.63) CRHR1ALDH1A1MAPK1
SCHEMBL2070099 0.74 CRHR1 (0.62) CRHR1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2522670-A1 Heterocyclic CRF receptor antagonists Takeda Pharmaceutical Company Limited (JP) 2012-11-14 EP disclosed
US-7897607-B2 Cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-01 US disclosed
US-7897607-B2 Cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-01 US disclosed
US-7897607-B2 Cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-01 US disclosed
US-20070179165-A1 Cyclic compounds GYORKOS ALBERT C 2007-08-02 US disclosed
US-20070179165-A1 Cyclic compounds GYORKOS ALBERT C 2007-08-02 US disclosed
US-20070179165-A1 Cyclic compounds GYORKOS ALBERT C 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179165-A1 Cyclic compounds CRHR1, CRHR2, MC2R CRHR1 1/4885TSHR 311/4885MAPK13 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.